Bioray Biotech Co., Ltd
Bioray Biotech Co., Ltd engages in the production, research, and sells health foods, immune cell products, and precision testing services in Taiwan. It offers health care products, including various functional foods and supplements; medicinal fungi; immune cell products; and precision medicine services, such as immunology, cell division, and specialized laboratory testing. The company is also inv… Read more
Bioray Biotech Co., Ltd (7561) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 0.038x
Based on the latest financial reports, Bioray Biotech Co., Ltd (7561) has a cash flow conversion efficiency ratio of 0.038x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$16.81 Million) by net assets (NT$439.96 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Bioray Biotech Co., Ltd - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Bioray Biotech Co., Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Bioray Biotech Co., Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bioray Biotech Co., Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
aap Implantate AG
F:AAQ1
|
-0.070x |
|
Cs Holdings
KO:000590
|
0.007x |
|
Apexindo Pratama Duta Tbk
JK:APEX
|
0.129x |
|
Huron Valley Bancorp Inc
PINK:HVLM
|
N/A |
|
Delta Israel Brands Ltd
TA:DLTI
|
0.165x |
|
Pacgold Ltd
AU:PGO
|
-0.030x |
|
Yw Company Limited
KQ:051390
|
0.072x |
|
Jinzisheng Holding Group
PINK:JGHG
|
0.040x |
Annual Cash Flow Conversion Efficiency for Bioray Biotech Co., Ltd (2019–2024)
The table below shows the annual cash flow conversion efficiency of Bioray Biotech Co., Ltd from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$420.73 Million | NT$16.65 Million | 0.040x | +2353.95% |
| 2023-12-31 | NT$433.90 Million | NT$-762.00K | -0.002x | -132.00% |
| 2022-12-31 | NT$451.47 Million | NT$2.48 Million | 0.005x | -77.38% |
| 2021-12-31 | NT$363.92 Million | NT$8.83 Million | 0.024x | +438.77% |
| 2020-12-31 | NT$371.75 Million | NT$1.67 Million | 0.005x | -96.39% |
| 2019-12-31 | NT$499.68 Million | NT$62.31 Million | 0.125x | -- |